Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis
ecancermedicalscience · 12.02.2025 · 19
DOI: 10.3332/ecancer.2025.1844 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ecancermedicalscience, online erschienen am 12.02.2025. Verfasst von Chalothorn Wannaphut und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/objectives: Sodium-glucose-co-transporter-2 (SGLT2) inhibitors have shown benefit in reducing cardiovascular disease outcomes in diabetes patients. Anthracycline therapy is associated with a risk of cardiomyopathy. However, the impact of SGLT2 inhibitors in the prevention of cardiomyopathy and heart failure in cancer patients undergoing anthracycline treatment remains unclear. Thus, we conducted a systematic review and meta-analysis to explore the effect of the prevention of cardiovascular outcomes in patients with cancer and diabetes who had received anthracycline therapy.
Methods
We systematically reviewed Medline and EMBASE databases from inception to January 2024 for studies focusing on cancer patients with a history of anthracycline therapy. Eligible studies had to report relative risk (RR) with 95% confidence intervals (CIs) for the clinical endpoints of mortality outcomes and the risk of heart failure exacerbation, comparing cohorts with and without SGLT2 inhibitor use.
Results
Our study included four retrospective cohort studies in the meta-analysis (n = 6,708, 24% received SGLT2). There was significantly lower all-cause mortality in the SGLT2 inhibitors group (pooled RR of 0.52, 95% CI 0.35-0.77, I 2 64%). However, there were no differences in the risk of heart failure exacerbation (pooled RR of 0.67, 95% CI 0.39-1.14, I 2 17%).
Conclusion
Our study found that anthracycline-treated cancer patients using SGLT2 inhibitors experienced lower all-cause mortality compared to the control group. A randomised clinical trial is necessary to further elucidate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
- Department of Medicine, Albert Einstein Healthcare Network, Philadelphia, PA, USA.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
- Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX, USA.
- Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
- Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, USA.
Zitieren
APA
Wannaphut, C., Wattanachayakul, P., Saowapa, S., Ponvilawan, B., Tanariyakul, M., Kewcharoen, J., Yingchoncharoen, P., Suenghataiphorn, T., Aiumtrakul, N., & Acoba, J. (2025). Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis. ecancermedicalscience, 19. https://doi.org/10.3332/ecancer.2025.1844
Vancouver
Wannaphut C, Wattanachayakul P, Saowapa S, Ponvilawan B, Tanariyakul M, Kewcharoen J, et al. Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis. ecancermedicalscience. 2025;19. doi:10.3332/ecancer.2025.1844
BibTeX
@article{Wannaphut2025,
author = {Wannaphut, Chalothorn and Wattanachayakul, Phuuwadith and Saowapa, Sakditad and Ponvilawan, Ben and Tanariyakul, Manasawee and Kewcharoen, Jakrin and Yingchoncharoen, Pitchaporn and Suenghataiphorn, Thanathip and Aiumtrakul, Noppawit and Acoba, Jared},
title = {Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis},
journal = {ecancermedicalscience},
year = {2025},
volume = {19},
doi = {10.3332/ecancer.2025.1844}
}
EUVIMED